A fixed-dose ophthalmic decongestant combination used for the symptomatic relief of ocular redness and irritation. Naphazoline is a direct-acting sympathomimetic (alpha-adrenergic agonist) that causes vasoconstriction of the conjunctival blood vessels. Phenylephrine is also a selective alpha-1 adrenergic agonist that provides additional vasoconstrictive and decongestant effects. The combination provides rapid and prolonged relief from redness associated with minor eye irritations.
Adult: Instill 1 or 2 drops into the affected eye(s) every 3 to 4 hours as needed for relief. Do not exceed 4 doses in 24 hours.
Note: 1. Wash hands before use. 2. Tilt head back. 3. Gently pull lower eyelid down to form a pouch. 4. Hold dropper directly over eye and instill the prescribed number of drops. 5. Close eyes gently for 1-2 minutes. Apply gentle pressure with finger to the corner of the eye (nasolacrimal duct) for about 1 minute to minimize systemic absorption. 6. Do not touch the dropper tip to any surface to avoid contamination. 7. Wait at least 5 minutes before instilling any other eye medication.
Both components are direct-acting sympathomimetic amines. They act on alpha-adrenergic receptors (primarily alpha-1) present on the precapillary and postcapillary arterioles of the conjunctiva. Receptor activation stimulates smooth muscle contraction, leading to vasoconstriction. This reduces blood flow and fluid exudation, thereby decreasing edema and redness (conjunctival hyperemia). The combination provides a synergistic decongestant effect.
Pregnancy: Category C: Animal reproduction studies have not been conducted. Use only if clearly needed. Potential for fetal vasoconstriction exists with significant systemic absorption. Short-term, infrequent OTC use is likely low risk, but should be avoided unless directed by a physician.
Driving: May cause temporary blurred vision. Patients should not drive or operate machinery until vision clears.
| Monoamine Oxidase Inhibitors (MAOIs) e.g., Phenelzine, Tranylcypromine | Risk of severe hypertensive crisis due to potentiation of sympathomimetic effects. | Contraindicated |
| Tricyclic Antidepressants (TCAs) e.g., Amitriptyline | May potentiate pressor effects of phenylephrine. | Major |
| Beta-blockers (e.g., Propranolol, Timolol eye drops) | Unopposed alpha-adrenergic activity may lead to hypertensive episodes and bradycardia. | Major |
| Other Sympathomimetics (e.g., systemic decongestants like Pseudoephedrine) | Additive cardiovascular effects (hypertension, tachycardia). | Moderate |
| Digoxin | Increased risk of cardiac arrhythmias. | Moderate |
| Ergot Alkaloids (e.g., Ergotamine) | Increased vasoconstrictive effects, risk of peripheral ischemia. | Major |
Same composition (Naphazoline (0.05%) + Phenylephrine (0.12%)), different brands: